BRISTOL-MYERS SQUIBB COMPANY (BMY) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $4.16B; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $13.47B; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $4.16B | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $4.16B |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $13.47B | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $13.47B |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 65.31B USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Amounts owed to suppliers | 4.16B USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Deferred Revenue · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Noncurrent · Deferred Revenue · Deferred Revenue, Current |
| Reported other obligations due within one year | 13.47B USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 4.34B USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Deferred Revenue · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $13.47B
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Income taxes payable | $806.00M |
| Operating lease obligations | $1.93B |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.16B | (m) | $13.47B | (m) | $65.31B | (m) | (m) | (m) | $4.34B | (m) |
| 2026-03-31 | (m) | $4.23B | (m) | $12.62B | (m) | $66.37B | (m) | (m) | (m) | $4.85B | (m) |
| 2025-12-31 | (m) | $3.58B | (m) | $17.58B | (m) | $71.53B | (m) | (m) | (m) | $5.04B | (m) |
| 2025-09-30 | (m) | $4.29B | (m) | $19.34B | (m) | $78.29B | (m) | (m) | (m) | $5.46B | (m) |
| 2025-06-30 | (m) | $5.43B | (m) | $17.39B | (m) | $77.19B | (m) | (m) | (m) | $4.94B | (m) |
| 2025-03-31 | (m) | $4.00B | (m) | $16.51B | (m) | $74.98B | (m) | (m) | (m) | $4.48B | (m) |
| 2024-12-31 | (m) | $3.60B | (m) | $18.13B | (m) | $76.22B | (m) | (m) | (m) | $4.47B | (m) |
| 2024-09-30 | (m) | $3.47B | (m) | $18.09B | (m) | $76.47B | (m) | (m) | (m) | $4.73B | (m) |
| 2024-06-30 | (m) | $3.75B | (m) | $15.98B | (m) | $77.58B | $52.22B | (m) | (m) | $4.99B | (m) |
| 2024-03-31 | (m) | $3.54B | (m) | $16.09B | (m) | $82.48B | $55.35B | (m) | (m) | $6.73B | (m) |
| 2023-12-31 | (m) | $3.26B | (m) | $15.88B | (m) | $65.67B | (m) | (m) | (m) | $6.42B | (m) |
| 2023-09-30 | (m) | $2.81B | (m) | $15.18B | (m) | $62.20B | (m) | (m) | (m) | $6.20B | (m) |
| 2023-06-30 | (m) | $3.07B | (m) | $14.06B | (m) | $61.46B | (m) | (m) | (m) | $5.90B | (m) |
| 2023-03-31 | (m) | $3.19B | (m) | $13.14B | (m) | $62.40B | (m) | (m) | (m) | $6.66B | (m) |
| 2022-12-31 | (m) | $3.04B | (m) | $14.59B | (m) | $65.70B | (m) | (m) | (m) | $6.59B | (m) |
| 2022-09-30 | (m) | $2.60B | (m) | $14.20B | (m) | $65.46B | (m) | (m) | (m) | $6.68B | (m) |
| 2022-06-30 | (m) | $2.88B | (m) | $13.08B | (m) | $67.70B | (m) | (m) | (m) | $6.64B | (m) |
| 2022-03-31 | (m) | $2.94B | (m) | $12.36B | (m) | $71.39B | (m) | (m) | (m) | $7.31B | (m) |
| 2021-12-31 | (m) | $2.95B | (m) | $13.97B | (m) | $73.31B | (m) | (m) | (m) | $7.33B | (m) |
| 2021-09-30 | (m) | $2.69B | (m) | $13.70B | (m) | $73.61B | (m) | (m) | (m) | $7.52B | (m) |
| 2021-06-30 | (m) | $3.61B | (m) | $12.73B | (m) | $73.92B | (m) | (m) | (m) | $7.50B | (m) |
| 2021-03-31 | (m) | $2.97B | (m) | $12.58B | (m) | $74.76B | (m) | (m) | (m) | $7.69B | (m) |
| 2020-12-31 | (m) | $2.71B | (m) | $14.03B | (m) | $80.60B | (m) | (m) | (m) | $7.78B | (m) |
| 2020-09-30 | (m) | $2.44B | (m) | $14.44B | (m) | $75.31B | (m) | (m) | (m) | $7.57B | (m) |
| 2020-06-30 | (m) | $2.85B | (m) | $15.75B | (m) | $78.92B | (m) | (m) | (m) | $7.49B | (m) |
| 2020-03-31 | (m) | $3.07B | (m) | $12.30B | (m) | $79.31B | (m) | (m) | (m) | $10.70B | (m) |
| 2019-12-31 | (m) | $2.44B | (m) | $12.51B | (m) | $78.25B | (m) | (m) | (m) | $10.10B | (m) |
| 2019-09-30 | (m) | $1.89B | (m) | $8.03B | (m) | $39.68B | (m) | (m) | (m) | $1.88B | (m) |
| 2019-06-30 | (m) | $2.00B | (m) | $7.16B | (m) | $39.01B | (m) | (m) | (m) | $1.90B | (m) |
| 2019-03-31 | (m) | $1.98B | (m) | (m) | (m) | $19.52B | (m) | (m) | (m) | $1.51B | (m) |
| 2018-12-31 | (m) | $1.89B | (m) | (m) | (m) | $20.86B | $6.89B | (m) | (m) | $1.05B | (m) |
| 2018-09-30 | (m) | $1.77B | (m) | (m) | (m) | $19.98B | $6.93B | (m) | (m) | $1.00B | (m) |
| 2018-06-30 | (m) | $1.87B | (m) | (m) | (m) | $20.22B | $6.93B | (m) | (m) | $1.07B | (m) |
| 2018-03-31 | (m) | $1.73B | (m) | (m) | (m) | $20.18B | $7.02B | (m) | (m) | $1.10B | (m) |
| 2017-12-31 | (m) | $2.25B | (m) | (m) | (m) | $21.70B | (m) | (m) | (m) | $1.16B | (m) |
| 2017-09-30 | (m) | $1.70B | (m) | (m) | (m) | $19.06B | (m) | (m) | (m) | $1.16B | (m) |
| 2017-06-30 | (m) | $1.55B | (m) | (m) | (m) | $18.59B | (m) | (m) | (m) | $1.18B | (m) |
| 2017-03-31 | (m) | $1.50B | (m) | (m) | (m) | $18.40B | (m) | (m) | (m) | $1.20B | (m) |
| 2016-12-31 | (m) | $1.66B | (m) | (m) | (m) | $17.36B | (m) | (m) | (m) | $1.28B | (m) |
| 2016-09-30 | (m) | $1.41B | (m) | (m) | (m) | $17.95B | (m) | (m) | (m) | $1.64B | (m) |
| 2016-06-30 | (m) | $1.50B | (m) | (m) | (m) | $17.75B | (m) | (m) | (m) | $1.80B | (m) |
| 2016-03-31 | (m) | $1.54B | (m) | (m) | (m) | $17.34B | (m) | (m) | (m) | $1.69B | (m) |
| 2015-12-31 | (m) | $1.56B | (m) | (m) | (m) | $17.32B | (m) | (m) | (m) | $480.00M | (m) |
| 2015-09-30 | (m) | $1.25B | (m) | (m) | (m) | $16.51B | (m) | (m) | (m) | $468.00M | (m) |
| 2015-06-30 | (m) | $1.84B | (m) | (m) | (m) | $16.66B | (m) | (m) | (m) | $475.00M | (m) |
| 2015-03-31 | (m) | $2.35B | (m) | (m) | (m) | $17.89B | (m) | (m) | (m) | $583.00M | (m) |
| 2014-12-31 | (m) | $2.49B | (m) | (m) | (m) | $18.77B | (m) | (m) | (m) | $618.00M | (m) |
| 2014-09-30 | (m) | $2.57B | (m) | (m) | (m) | $18.25B | (m) | (m) | (m) | $618.00M | (m) |
| 2014-06-30 | (m) | $2.40B | $461.00M | (m) | (m) | $18.12B | (m) | (m) | (m) | $624.00M | (m) |
| 2014-03-31 | (m) | $2.50B | $499.00M | (m) | (m) | $17.89B | (m) | (m) | (m) | $616.00M | (m) |
| 2013-12-31 | (m) | $2.56B | $468.00M | (m) | (m) | $23.36B | (m) | (m) | (m) | $625.00M | (m) |
| 2013-09-30 | (m) | $2.47B | $373.00M | (m) | (m) | $22.09B | (m) | (m) | (m) | $665.00M | (m) |
| 2013-06-30 | (m) | $2.35B | $364.00M | (m) | (m) | $21.88B | (m) | (m) | (m) | $649.00M | (m) |
| 2013-03-31 | (m) | $2.08B | $271.00M | (m) | (m) | $22.26B | (m) | (m) | (m) | $459.00M | (m) |
| 2012-12-31 | (m) | $2.20B | $339.00M | (m) | (m) | $22.26B | (m) | (m) | (m) | $475.00M | (m) |
| 2012-09-30 | (m) | $2.08B | $211.00M | (m) | (m) | $22.14B | (m) | (m) | (m) | $464.00M | (m) |
| 2012-06-30 | (m) | $2.13B | (m) | (m) | (m) | $15.86B | (m) | (m) | (m) | $703.00M | (m) |
| 2012-03-31 | (m) | $2.38B | (m) | (m) | (m) | $16.16B | (m) | (m) | (m) | $656.00M | (m) |
| 2011-12-31 | (m) | $2.60B | $113.00M | (m) | (m) | $17.10B | (m) | (m) | (m) | $491.00M | (m) |
| 2011-09-30 | (m) | $2.29B | (m) | (m) | (m) | $15.58B | (m) | (m) | (m) | $467.00M | (m) |
| 2011-06-30 | (m) | $2.40B | (m) | (m) | (m) | $15.69B | (m) | (m) | (m) | $443.00M | (m) |
| 2011-03-31 | (m) | $2.04B | (m) | (m) | (m) | $14.95B | (m) | (m) | (m) | $438.00M | (m) |
| 2010-12-31 | (m) | $1.98B | $227.00M | (m) | (m) | $15.44B | (m) | (m) | (m) | $424.00M | (m) |
| 2010-09-30 | (m) | $1.73B | $1.18B | (m) | $409.00M | $16.03B | (m) | $289.00M | $893.00M | $409.00M | $0.00 |
| 2010-06-30 | (m) | $1.68B | $1.19B | (m) | $409.00M | $15.48B | (m) | $275.00M | $915.00M | $409.00M | $0.00 |
| 2010-03-31 | (m) | $1.75B | $1.23B | (m) | $416.00M | $15.52B | (m) | $265.00M | $961.00M | $416.00M | $0.00 |
| 2009-12-31 | (m) | $1.71B | $1.19B | (m) | $422.00M | $16.22B | (m) | $237.00M | $949.00M | $422.00M | $0.00 |
| 2009-09-30 | (m) | $1.80B | $1.21B | (m) | $408.00M | $16.58B | (m) | $276.00M | $934.00M | $408.00M | $0.00 |
| 2009-06-30 | (m) | (m) | $1.14B | (m) | $430.00M | $15.87B | (m) | $267.00M | $872.00M | $430.00M | $0.00 |
| 2008-12-31 | (m) | (m) | $1.07B | (m) | $441.00M | $17.28B | (m) | $277.00M | $791.00M | $441.00M | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |